Amgen Inc.

Simon J Hedley

Jonathan B Houze

Xiaoqi Chen

Nobuko Nishimura

Zhihua Ma

David John Kopecky

Zice Fu

Paul John Dransfield

Vatee Pattaropong

Xiaodong Wang

Richard V Connors

Steven H Olson

Julie Anne Heath

Mikkel V Debenedetto

Su-Jen Lai

Julio Cesar Medina

Lawrence R McGee

Ning Chen

Xiaohui Du

Kevin Chao Yang

Matthew R Kaller

Jeffrey Thomas Mihalic

Ted Charles Judd

Daniel B Horne

Jeffrey Deignan

Alan C Cheng

Robert P Farrell

Gayathri Swaminath

Frank Kayser

Wen-Chen Yeh

Yinhong Chen

Aarif Yusuf Khakoo

Kevin Yang

James S Harvey

Jason S Tedrow

Steven Mennen

Beatriz Dominguez

Amin Bornadel

Serena Bisagni

Jacques Lepaih

Ahir Pushpanath

Iustina Slabu

Julio C Medina

Lawrence R Mcgee

Jeffrey T Mihalic

Jonathan Houze

Ted C Judd

A method for reducing a substrate selected from 2-methyl-5-nitropyridine and methyl 4-(2-fluoro-3-nitrobenzyl)piperazine-1-carboxylate is provided catalysed by a nitroreductase and a disproportionation agent.

Method of reducing aromatic nitro compounds

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

Growing community of inventors

Thousand Oaks, CA, United States of America

Simon J Hedley